



UNIVERSITY OF LEEDS

This is a repository copy of *Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/133357/>

Version: Supplemental Material

Article:

Ratnakumaran, R, To, N, Gracie, DJ orcid.org/0000-0001-9616-981X et al. (8 more authors) (2018) Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. *Scandinavian Journal of Gastroenterology*, 53 (6). pp. 700-707. ISSN 0036-5521

<https://doi.org/10.1080/00365521.2018.1464203>

© 2018 Informa UK Limited, trading as Taylor & Francis Group. This is an author produced version of a paper published in *Scandinavian Journal of Gastroenterology*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 3: Infliximab Drug and Antibody Levels Prior to the Switch to CT-P13 and Treatment Response 12 Months Post-switch.

Treatment Response	Mean Infliximab Trough Level in mg/L (SD)	Mean Total Anti-infliximab Antibody Level in AU/ml (SD)
Remission	5.1 (3.8)	12.4 (47.5)
Responders	4.2 (3.2)	14.7 (24.5)
Secondary non-responders	3.1 (2.7)	66.2 (119.7)
Adverse Events	2.9 (2.9)	9.2 (18.5)